BioSpace

Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%

Actinogen Medical’s lead program for its sole pipeline candidate has failed a late-stage study, but the Australian biotech still plans on taking the findings to the FDA for a path forward.

By BioSpace

1 min read
Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights